Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria
This study has been completed.
Sponsors and Collaborators: Menzies School of Health Research
Wellcome Trust
National Health and Medical Research Council, Australia
MSHR
NIHRD
Rumah Sakit Mitra Masyarakat Hospital
University of Utah
University of Sydney
Information provided by: Menzies School of Health Research
ClinicalTrials.gov Identifier: NCT00147368
  Purpose

Acute falciparum malaria is associated with low plasma arginine and impaired nitric oxide (NO) production. Both are associated with poor outcome. This study will examine the safety and effect of escalating doses of arginine in falciparum malaria. It will determine whether arginine can increase NO production and have an effect on NO-dependent physiological measurements. The hypothesis is that arginine: will be safe in falciparum malaria; will return plasma arginine concentration to normal/supranormal levels; will increase systemic and exhaled NO; reduces oxidant stress; and improves a number of NO-dependent physiological measures of relevance to malaria.


Condition Intervention Phase
Malaria, Falciparum
Drug: intravenous (IV) arginine
Phase I
Phase II

MedlinePlus related topics: Malaria
Drug Information available for: Arginine Arginine hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Pharmacokinetics/Dynamics Study
Official Title: Pharmacokinetic-Pharmacodynamic Study of Adjunctive Arginine in Falciparum Malaria

Further study details as provided by Menzies School of Health Research:

Primary Outcome Measures:
  • exhaled and systemic nitric oxide production
  • endothelial function

Secondary Outcome Measures:
  • safety
  • pharmacokinetic (PK) parameters
  • pharmacodynamic (PD) parameters
  • oxidant stress
  • gas transfer
  • endothelial activation
  • a priori subgroup analysis: endothelial function in those with baseline impairment of function

Estimated Enrollment: 50
Study Start Date: February 2005
Study Completion Date: December 2007
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ages 18-60 years
  2. P. falciparum parasitemia (1,000-100,000 parasites/ul).
  3. Clinical syndrome consistent with malaria associated with documented fever (axillary temperature > 38℃) or self-reported history of fever in the last 48 hours with no other cause present
  4. Commenced oral quinine ≤ 18 hours prior to scheduled commencement of arginine
  5. An indication for hospital admission (eg relative cannot look after/supervise treatment at home but not having any warning signs or severe malaria criteria in "exclusion criteria" below)
  6. Informed consent obtained

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Mixed infection with P. falciparum and P. vivax
  3. Warning signs of altered mental state and inability to sit unaided
  4. Features of severe/complicated malaria
  5. Diabetes
  6. Systolic blood pressure (BP) < 100 mmHg
  7. Serious underlying disease (cardiac, hepatic, kidney)
  8. Initial iSTAT test showing any of the following values:

    • glucose < 4 mmol/L;
    • K+ ≥ 4.2 meq/L;
    • Cl- > 106 meq/L;
    • HCO3- < 20 meq/L.
  9. Known allergy to L-arginine
  10. Concurrent therapy with any of the following medications:

    • spironolactone;
    • oral nitrates;
    • phosphodiesterase inhibitor (eg sildenafil [Viagra]);
    • alpha-blocking antihypertensive agents (eg prazosin);
    • L-arginine.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00147368

Locations
Indonesia
RSMM Hospital
Timika, Indonesia
Sponsors and Collaborators
Menzies School of Health Research
Wellcome Trust
National Health and Medical Research Council, Australia
MSHR
NIHRD
Rumah Sakit Mitra Masyarakat Hospital
University of Utah
University of Sydney
Investigators
Principal Investigator: Nick M Anstey, MBBS MSHR
  More Information

Publications:
Publications indexed to this study:
Responsible Party: Menzies School of Health Research ( Nicholas Anstey )
Study ID Numbers: arginine, GR071614MA - Wellcome Trust
Study First Received: September 6, 2005
Last Updated: May 30, 2008
ClinicalTrials.gov Identifier: NCT00147368  
Health Authority: Australia: Human Research Ethics Committee

Keywords provided by Menzies School of Health Research:
falciparum
malaria
arginine

Study placed in the following topic categories:
Protozoan Infections
Parasitic Diseases
Malaria
Malaria, Falciparum

Additional relevant MeSH terms:
Coccidiosis

ClinicalTrials.gov processed this record on January 16, 2009